8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

May 8, 2007
Date of Report (Date of earliest event reported)

BIOLASE TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of Incorporation) 000-19627
(Commission File Number) 87-0442441
(IRS Employer
Identification Number)

4 Cromwell
Irvine, California 92618
(Address of principal executive offices) (Zip Code)

(949) 361-1200
(Registrant’s telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 2.02 Results of Operations and Financial Condition
	Item 9.01 Financial Statements and Exhibits
SIGNATURES
EXHIBIT 99.1

Item 2.02 Results of Operations and Financial Condition

     On May 8, 2007, BIOLASE Technology, Inc. (“Biolase”), issued a press release announcing its financial results for the completed quarter ended March 31, 2007. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K and the press release is not incorporated by reference into any filings of Biolase, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing, unless explicitly incorporated by specific reference into such filing.

Item 9.01 Financial Statements and Exhibits

     (d) Exhibits.

99.1    Press Release of BIOLASE Technology, Inc., dated May 8, 2007

2

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOLASE TECHNOLOGY, INC.
Date: May 8, 2007	By:	/s/ Richard L. Harrison
		Richard L. Harrison
		Executive Vice President, Chief Financial Officer & Secretary

3

EX-99.1

Exhibit 99.1

NEWS RELEASE for May 8, 2007

BIOLASE REPORTS FIRST QUARTER 2007 RESULTS

IRVINE, CA (May 8, 2007) — BIOLASE Technology, Inc. (NASDAQ:BLTI), the world’s leading dental laser company, today reported operating results for its first quarter ended March 31, 2007. These results are in line with the preliminary results that were announced on April 11.

Net revenue for the quarter ended March 31, 2007 was $15.1 million compared with $16.9 million for the first quarter of 2006. Net domestic revenue for the first quarter of 2007 was $8.7 million as compared with $10.4 million in the 2006 first quarter. Net international revenue in the first quarters of 2007 and 2006 was $6.4 million and $6.5 million, respectively.

Gross profit for the first quarter of 2007 improved to 54 percent of net revenue as compared with 52 percent of net revenue in the same period of 2006. Operating expenses in the 2007 first quarter declined by nine percent, or $1.0 million, to $10.0 million from $11.0 million in the first quarter of 2006. Net loss for the quarter ended March 31, 2007 narrowed to $1.7 million, or $0.07 per diluted share, compared with a net loss of $2.3 million, or $0.10 per diluted share, for the first quarter of 2006.

President and CEO Jeffrey W. Jones commented, “During the quarter, we continued to make progress in key operational areas, especially in our ongoing cost containment programs, which we expect will yield significant benefits as revenue trends improve in the coming periods. Despite lower revenues from products and services, the gross margin as a percentage of sales was only 0.7 percent lower in the first quarter this year compared with the same quarter of 2006. Additionally, our efforts resulted in a nine percent operating expense reduction in this year’s first quarter as compared to last year’s. We believe our current infrastructure and cost structure position us well for bottom-line improvement in 2007.”

Jones continued, “We have been highly engaged with the management of Sullivan-Schein Dental with the shared goal of benefiting from our experience in the first quarter. As a result, we are refining the allocation of our sales representatives’ time between selling and relationship-building activities with the Schein sales representatives in the field, and we have kicked off programs we believe will have a positive impact on sales. We’re getting an excellent start in our first full quarter of selling the new ezlase™ 940 soft-tissue diode dental laser system. And, we are already launching new accessories and disposables to expand what a dentist can do with the Waterlase MD™ and increase its efficiency and speed. Currently, we are launching our single patient use disposable ZipTips™ and our new Waterlase MD Gold™ handpiece. This is just the beginning of exciting new initiatives we believe will contribute to significant revenue growth, with increased consumables sales, in 2007.”

Conference Call

As previously announced, the Company will host a conference call today at 9:00 a.m. Eastern Time to discuss its operating results for the first quarter ended March 31, 2007 and to answer questions.

To listen to the conference call live via the internet, visit the Investors section of the BIOLASE website at www.biolase.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. A replay will be available on BIOLASE’s website.

To listen to the conference call live via telephone, please dial (800) 632-4307 from the U.S. or, for international callers, please dial (973) 935-8761, approximately 10 minutes before the start time. A telephone replay will be available for two days by dialing (877) 519-4471 from the U.S., or (973) 341-3080 for international callers, and entering passcode number 8745491.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: Jeffrey W. Jones, President & CEO; Richard L. Harrison, Executive Vice President and CFO of BIOLASE Technology, Inc., +1-949-361-1200; or Jill Bertotti, of Allen & Caron, +1-949-474-4300.

- TABLE FOLLOWS -

BIOLASE TECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(in thousands, except per share amounts)

	Three Months Ended
	March 31,
	2007			2006
Products and services revenue	$	14,100		$	16,784
License fees and royalty revenue		960			96
Net revenue		15,060			16,880
Cost of revenue		6,923			8,116
Gross profit		8,137			8,764
Other income, net		—			16
Operating expenses:
Sales and marketing		6,393			6,080
General and administrative		2,377			3,289
Engineering and development		1,210			1,198
Patent infringement legal settlement		—			432
Total operating expenses		9,980			10,999
Loss from operations		(1,843	)		(2,219	)
Non-operating income, net		189			17
Loss before income tax provision		(1,654	)		(2,202	)
Income tax provision		69			82
Net loss	$	(1,723	)	$	(2,284	)
Net loss per share:
Basic	$	(0.07	)	$	(0.10	)
Diluted	$	(0.07	)	$	(0.10	)
Shares used in the calculation of net loss per share:
Basic		23,791			23,272
Diluted		23,791			23,272

BIOLASE TECHNOLOGY, INC.

CONSOLIDATED BALANCE SHEETS (Unaudited)
(in thousands, except per share amounts)

	March 31, 2007			December 31, 2006
ASSETS
Current assets:
Cash and cash equivalents	$	12,789		$	14,676
Accounts receivable, less allowance of $1,207 and $1,357 in 2007 and 2006, respectively		12,286			15,193
Inventory, net		8,879			7,774
Prepaid expenses and other current assets		1,483			1,346
Total current assets		35,437			38,989
Property, plant and equipment, net		4,717			4,851
Intangible assets, net		1,379			1,469
Goodwill		2,926			2,926
Deferred tax asset		36			35
Other assets		309			308
Total assets	$	44,804		$	48,578
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	7,306		$	7,699
Accrued liabilities		6,785			8,560
Deferred revenue, current portion		5,277			5,431
Total current liabilities		19,368			21,690
Deferred tax liabilities		290			271
Deferred revenue, long-term		3,861			4,278
Other liabilities, long-term		518			373
Total liabilities		24,037			26,612
Stockholders’ equity:
Preferred stock, par value $0.001, 1,000 shares authorized, no shares issued and outstanding		—			—
Common stock, par value $0.001, 50,000 shares authorized, 25,771 and 25,741 shares issued and 23,808 and 23,777 shares outstanding in 2007 and 2006, respectively		26			26
Additional paid-in capital		111,973			111,415
Accumulated other comprehensive loss		230			108
Accumulated deficit		(75,063	)		(73,184	)
		37,166			38,365
Treasury stock (cost of 1,964 shares repurchased)		(16,399	)		(16,399	)
Total stockholders’ equity		20,767			21,966
Total liabilities and stockholders’ equity	$	44,804		$	48,578

# # # #